Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock?
Improving fundamentals are making Canopy harder to ignore.
Overview
Canopy Growth (NASDAQ: CGC) is getting closer to something marijuana investors have been waiting years to see: positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). The Canada-based cannabis company recently reported Q1 fiscal 2027 net revenue of about $57.4 million, up 13% year over year, with growth across every major business. Cannabis revenue increased 14%, and growth wasn't limited to one market.
Canadian medical cannabis revenue jumped 22% to about $18.5 million, Canadian adult-use revenue increased 10% to $21.3 million, and international cannabis revenue rose 10% to about $6.9 million. That's a much healthier revenue picture than Canopy has produced in recent years.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.